Is cetuximab active in patients with cisplatin-refractory squamous cell carcinoma of the head and neck?: Commentary

Nature Clinical Practice Oncology

Volumn 4, Issue 12, 2007, Pages 690-691

  Bonner, James A ^a   Keene, Kimberly S ^a  

^a The University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; PLATINUM DERIVATIVE;

CANCER CONTROL; CANCER RECURRENCE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HEAD AND NECK CARCINOMA; HUMAN; LOADING DRUG DOSE; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SHORT SURVEY; SKIN MANIFESTATION; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME; UNSPECIFIED SIDE EFFECT;

EID: 36549030430     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc0962     Document Type: Short Survey

References (4)

1. Forastiere AA et al. (1992) Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: A Southwest Oncology Group (SWOG) study. J Clin Oncol 10: 1245-1251
2. Cunningham D et al. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337-345
3. Forastiere AA (2007) Epidermal growth factor receptor inhibition in head and neck cancer- more insights, but more questions. J Clin Oncol 25: 2152-2155
4. Vokes EE et al. (2005) A phase I study of erlotinib and bevacizurnab for recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 23 (Suppl 16): S501